HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- Status
- UNKNOWN
- Phase
- N/A
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- Status
- RECRUITING
- Phase
- PHASE2
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting
- Status
- UNKNOWN
- Phase
- N/A
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
- Status
- RECRUITING
- Phase
- PHASE2
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3